James Comben
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James Comben has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Anna Sofia Trigos
Peter MacCallum Cancer Centre
2 shared publications - Anthony T. Papenfuss
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
2 shared publications Anupama Pasam
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
2 shared publications- Belinda S. Parker
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
2 shared publications Benjamin Blyth
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
2 shared publications- Catherine Mitchell
Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
2 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer
The evolution to metastatic disease is a major determinant of cancer mortality. Cancer evolution involves a complex interplay between intrinsic genetics and transcriptional alterations and the microenvironment. To define mechanisms underpinning metastatic heterogeneity in late-stage disease, we focus on metastatic castration-resistant prostate cancer and employed single-cell multi-omics and whole-genome sequencing to deeply profile 34 metastatic lesions obtained from 9 patients through rapid autopsy. We find evolutionary convergence of intra-tumour heterogeneity, characterised by recurrent tumour populations acting as critical functional components of the tumour ecosystem, irrespective of clonal and microenvironmental backgrounds. We find little evidence of the microenvironment driving transcriptional heterogeneity, but there are signatures of co-adaptation between the microenvironment and tumour cells. In contrast, clonal evolution primarily foster widespread transcriptional changes that did not result in de novo functional states. Intra-patient functional convergence of tumour ecosystems across metastases indicates system-level selection pressures that drive the heterogeneity landscape of metastatic castration-resistant prostate cancer. Our findings reveal functional evolutionary convergence of metastatic disease into distinct intra-tumour subpopulations, identifying critical determinants for therapeutic targeting.
- 19 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessRecurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer
The evolution to metastatic disease is a major determinant of cancer mortality. Cancer evolution involves a complex interplay between intrinsic genetics and transcriptional alterations and the microenvironment. To define mechanisms underpinning metastatic heterogeneity in late-stage disease, we focus on metastatic castration-resistant prostate cancer and employed single-cell multi-omics and whole-genome sequencing to deeply profile 34 metastatic lesions obtained from 9 patients through rapid autopsy. We find evolutionary convergence of intra-tumour heterogeneity, characterised by recurrent tumour populations acting as critical functional components of the tumour ecosystem, irrespective of clonal and microenvironmental backgrounds. We find little evidence of the microenvironment driving transcriptional heterogeneity, but there are signatures of co-adaptation between the microenvironment and tumour cells. In contrast, clonal evolution primarily foster widespread transcriptional changes that did not result in de novo functional states. Intra-patient functional convergence of tumour ecosystems across metastases indicates system-level selection pressures that drive the heterogeneity landscape of metastatic castration-resistant prostate cancer. Our findings reveal functional evolutionary convergence of metastatic disease into distinct intra-tumour subpopulations, identifying critical determinants for therapeutic targeting.
- Open Access
- 25 November 2025
- Published by Springer Nature in Research Square
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer
The evolution from low grade to metastatic tumour is a major determinant of cancer mortality. Cancer evolution involves a complex interplay between intrinsic genetics and transcriptional alterations and the microenvironment. To define mechanisms underpinning metastatic development, we focused on metastatic castration-resistant prostate cancer (mCRPC) and employed single-cell multi-omics and whole-genome sequencing to deeply profile 34 metastatic lesions from 9 patients by rapid autopsy. We found that intra-tumour heterogeneity is an indicator of key evolutionary processes, characterised by recurrent tumour populations acting as critical functional components of the tumour ecosystem, irrespective of clonal and microenvironmental backgrounds. Unexpectedly, microenvironments only played a limited role while clonal evolution primarily promoted transcriptional noise. Intra-patient functional convergence of tumour ecosystems was observed across metastases, showing system-level selection pressures that drive the heterogeneity landscape of mCRPC. Our findings reveal functional evolutionary convergence of metastatic disease into units of intra-tumour heterogeneity, identifying critical determinants for therapeutic targeting. *Co-senior authors: Anna S. Trigos & Shahneen Sandhu contributed equally to this work.
- 25 November 2025
- Published by Springer Nature in Research Square
Open AccessRecurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer
The evolution from low grade to metastatic tumour is a major determinant of cancer mortality. Cancer evolution involves a complex interplay between intrinsic genetics and transcriptional alterations and the microenvironment. To define mechanisms underpinning metastatic development, we focused on metastatic castration-resistant prostate cancer (mCRPC) and employed single-cell multi-omics and whole-genome sequencing to deeply profile 34 metastatic lesions from 9 patients by rapid autopsy. We found that intra-tumour heterogeneity is an indicator of key evolutionary processes, characterised by recurrent tumour populations acting as critical functional components of the tumour ecosystem, irrespective of clonal and microenvironmental backgrounds. Unexpectedly, microenvironments only played a limited role while clonal evolution primarily promoted transcriptional noise. Intra-patient functional convergence of tumour ecosystems was observed across metastases, showing system-level selection pressures that drive the heterogeneity landscape of mCRPC. Our findings reveal functional evolutionary convergence of metastatic disease into units of intra-tumour heterogeneity, identifying critical determinants for therapeutic targeting. *Co-senior authors: Anna S. Trigos & Shahneen Sandhu contributed equally to this work.